We just received data on a new analyst forecast for $RXRX. Vikram Purohit from Recursion Pharmaceuticals set a price target of 5.0 for RXRX.
To track analyst ratings and price targets for $RXRX, check out Quiver Quantitative's $RXRX forecast page.
$RXRX Insider Trading Activity
$RXRX insiders have traded $RXRX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has made 0 purchases and 7 sales selling 258,574 shares for an estimated $1,699,186.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RXRX Hedge Fund Activity
We have seen 192 institutional investors add shares of $RXRX stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 7,725,096 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $40,865,757
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 4,149,346 shares (+183.7%) to their portfolio in Q1 2025, for an estimated $21,950,040
- UBS GROUP AG added 2,565,137 shares (+85.4%) to their portfolio in Q1 2025, for an estimated $13,569,574
- ARK INVESTMENT MANAGEMENT LLC added 2,469,104 shares (+7.6%) to their portfolio in Q1 2025, for an estimated $13,061,560
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 2,315,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,246,350
- MORGAN STANLEY added 2,149,906 shares (+75.2%) to their portfolio in Q1 2025, for an estimated $11,373,002
- VANGUARD GROUP INC removed 1,722,017 shares (-5.1%) from their portfolio in Q1 2025, for an estimated $9,109,469
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
